Axsome Therapeutics (AXSM) Competitors $97.95 +0.12 (+0.12%) (As of 12:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXSM vs. GBT, CORT, RARX, AIMT, HRMY, SMMT, RPRX, VTRS, GMAB, and INSMShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Global Blood Therapeutics (GBT), Corcept Therapeutics (CORT), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Harmony Biosciences (HRMY), Summit Therapeutics (SMMT), Royalty Pharma (RPRX), Viatris (VTRS), Genmab A/S (GMAB), and Insmed (INSM). Axsome Therapeutics vs. Global Blood Therapeutics Corcept Therapeutics Ra Pharmaceuticals Aimmune Therapeutics Harmony Biosciences Summit Therapeutics Royalty Pharma Viatris Genmab A/S Insmed Global Blood Therapeutics (NASDAQ:GBT) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends. Is GBT or AXSM more profitable? Axsome Therapeutics has a net margin of -91.87% compared to Global Blood Therapeutics' net margin of -137.30%. Axsome Therapeutics' return on equity of -158.36% beat Global Blood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Global Blood Therapeutics-137.30% -170.37% -39.24% Axsome Therapeutics -91.87%-158.36%-37.46% Which has preferable valuation & earnings, GBT or AXSM? Axsome Therapeutics has higher revenue and earnings than Global Blood Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Blood Therapeutics$194.75M23.73-$303.09M-$5.01-13.67Axsome Therapeutics$291.49M16.07-$239.24M-$6.53-15.10 Do institutionals & insiders have more ownership in GBT or AXSM? 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.9% of Global Blood Therapeutics shares are held by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, GBT or AXSM? Global Blood Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Do analysts recommend GBT or AXSM? Axsome Therapeutics has a consensus target price of $124.93, indicating a potential upside of 26.68%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Global Blood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Blood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GBT or AXSM? In the previous week, Axsome Therapeutics had 33 more articles in the media than Global Blood Therapeutics. MarketBeat recorded 33 mentions for Axsome Therapeutics and 0 mentions for Global Blood Therapeutics. Axsome Therapeutics' average media sentiment score of 0.73 beat Global Blood Therapeutics' score of 0.52 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Global Blood Therapeutics Positive Axsome Therapeutics Positive Does the MarketBeat Community favor GBT or AXSM? Global Blood Therapeutics received 119 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 69.11% of users gave Axsome Therapeutics an outperform vote while only 64.97% of users gave Global Blood Therapeutics an outperform vote. CompanyUnderperformOutperformGlobal Blood TherapeuticsOutperform Votes56264.97% Underperform Votes30335.03% Axsome TherapeuticsOutperform Votes44369.11% Underperform Votes19830.89% SummaryAxsome Therapeutics beats Global Blood Therapeutics on 14 of the 18 factors compared between the two stocks. Ad TradingTips3 Dirt-Cheap Stocks You Can’t Afford to Ignore Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.68B$6.71B$5.18B$8.91BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-15.1011.13135.1217.44Price / Sales16.07393.321,248.6491.11Price / CashN/A49.2238.8936.42Price / Book50.329.096.305.92Net Income-$239.24M$153.75M$118.33M$224.86M7 Day Performance8.73%-1.48%-1.54%-0.45%1 Month Performance15.45%8.07%2.98%4.16%1 Year Performance57.39%39.26%36.39%27.33% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.7562 of 5 stars$97.95+0.1%$124.93+27.5%+64.9%$4.65B$291.49M-15.00589Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGBTGlobal Blood TherapeuticsN/A$68.49flatN/A+0.0%$4.62B$194.75M-13.67457News CoverageCORTCorcept Therapeutics4.8199 of 5 stars$59.60+9.8%N/A+127.4%$5.68B$482.38M47.30300Insider SellingShort Interest ↓Positive NewsRARXRa PharmaceuticalsN/A$47.99flatN/A+0.0%$2.27B$3M-20.7772AIMTAimmune TherapeuticsN/A$34.49flatN/AN/A$2.26BN/A-7.68228HRMYHarmony Biosciences4.8964 of 5 stars$36.08+3.4%N/A+39.7%$2.06B$582.02M17.10200Short Interest ↓SMMTSummit Therapeutics2.2018 of 5 stars$21.41+1.5%N/A+958.2%$15.79B$700,000.00-76.46105Gap UpRPRXRoyalty Pharma4.8091 of 5 stars$26.21-1.2%N/A-4.6%$15.55B$2.27B13.5880Positive NewsHigh Trading VolumeVTRSViatris1.4626 of 5 stars$12.96-1.7%N/A+45.3%$15.47B$15.43B-23.5638,000Earnings ReportInsider SellingGMABGenmab A/S4.2653 of 5 stars$23.08-0.1%N/A-32.6%$15.27B$2.39B22.412,204Short Interest ↑Analyst RevisionINSMInsmed3.9969 of 5 stars$73.54+2.6%N/A+195.4%$13.16B$305.21M-13.25373Positive News Related Companies and Tools Related Companies GBT Alternatives CORT Alternatives RARX Alternatives AIMT Alternatives HRMY Alternatives SMMT Alternatives RPRX Alternatives VTRS Alternatives GMAB Alternatives INSM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXSM) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts